



Atty Docket: 31-CD-5530

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

G. Ian Rowlandson : Group Art Unit: 3626

Serial No.: 09/751,023 : Examiner: Gottschalk, M. A.

Filed: December 29, 2000

Title: AUTOMATED SCHEDULING OF EMERGENCY PROCEDURE
BASED ON IDENTIFICATION OF HIGH-RISK PATIENT

Hon. Commissioner for Patents
Alexandria, VA 22313-1450

**DECLARATION OF INVENTOR SWEARING BACK OF
REFERENCE PURSUANT TO 37 CFR § 1.131**

I, IAN ROWLANDSON, hereby declare as follows:

I am the sole inventor of the invention described and claimed in patent application Serial No. 09/751,023 filed in the United States of America on December 29, 2000, and entitled AUTOMATED SCHEDULING OF EMERGENCY PROCEDURE BASED ON IDENTIFICATION OF HIGH-RISK PATIENT.

I conceived and reduced to practice the invention recited in claims 1-11 and 16-27 of the above-referenced patent application in the United States of America while in the employ of General Electric Company (hereinafter "GE").

The broad concept of the invention is recited in pending independent claims 1 and 16 in the above-referenced patent application. I believe that the Invention Disclosure Sheet annexed hereto (Exhibit A) shows that the broad concept was conceived as early as November 18, 1999.


The Invention Disclosure Sheet is dated November 18, 1999, signed by myself and witnessed on the same date by Mark Kohls and J.G. Miskowiec, both of GE.

The undersigned inventor is submitting this exhibit for the purpose of demonstrating that the system and method recited in the independent claims of the instant patent application had been conceived, in the U.S.A., as early as November 18, 1999 and was never abandoned or suppressed.

The undersigned inventor declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole inventor: IAN ROWLANDSON

Inventor's signature:



21 APR 06
DATE

Residence: Milwaukee, Wisconsin
Citizenship: United States of America
Post Office Address: 7641 North Santa Monica Blvd.
Milwaukee, WI 53217



GE Medical Systems Invention Disclosure Sheet

3000 North Grandview Blvd., W-710
P. O. Box 414, Waukesha WI 53188

GE Marquette
Cardiology Information

DEPARTMENT
SECTION

Docket No: 31-CD-5530

To: SUSAN DONAHUE, W-710
Patent Paralegal

Date: November 17, 1999

TITLE: Automated scheduling of the Cath Lab based on identification of patient with high probability of unstable angina / acute MI.

The 12SL ECG analysis program is able to identify those patients who have a high probability of unstable angina / acute MI. These patients are candidates for an emergency Cath Lab procedure known as Primary PTCA. Time-to-treatment is critical for this procedure. In-hospital patient mortality for Primary PTCA has been shown to vary from 2 to 22%, a 10-fold difference. Delay in getting the patient into the Cath Lab has been found to be the most important variable for reducing mortality and improving overall outcome.

The invention: The 12SL ECG analysis program can identify patients that are candidates for Primary PTCA; this program is available in all our ECG acquisition devices (including prehospital defibrillators) as well as the MUSE/Catalyst system (the GE/Marquette ECG storage system). Any ECG coming into the MUSE system can be analyzed for whether or not the patient is an emergency candidate for Primary PTCA. If a patient is identified by the MUSE system as a candidate for Primary PTCA, it automatically routes this information to the Cath Lab department. In addition, it automatically checks the schedule of any Cath Lab attached to the MUSE/Catalyst system. It can do this across facilities. It will schedule the procedure, optimizing for time-to-treatment and for Cath Labs that exhibit an appropriate volume of Primary PTCA procedures. The MUSE system will automatically notify the emergency medical unit of where to route the patient and it will also notify the Cath Lab department that a candidate patient is on their way for treatment. Via manual methods, it has already been shown that this technique reduces time-to-treatment by 50%.

<u>JAN ROWLANDSON</u>		
(1st Inventor)		
<u>[Signature]</u>	<u>514-362-2075</u>	<u>18 NOV 99</u>
(2nd Inventor)		
(3rd Inventor)		
Print Inventor* Name/ Full Signature Above	Phone #	Date

* If first time inventor or changes have occurred since last invention fill in MEF84 "INVENTOR DATA SHEET".

Witnessed and Understood By Me: MARK KOHL [Signature] 18 Nov 99
(SIGNATURE) (DATE)

Witnessed and Understood By Me: JG MISKOWIEC [Signature] 11/18/99
(SIGNATURE) (DATE)